CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach. - Université de Lille Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) The Lancet Haematology Année : 2023

CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach.

Peter Dreger
  • Fonction : Auteur
Paolo Corradini
  • Fonction : Auteur
John G. Gribben
  • Fonction : Auteur
Bertram Glass
  • Fonction : Auteur
Mats Jerkeman
  • Fonction : Auteur
Marie Jose Kersten
  • Fonction : Auteur
Alberto Mussetti
  • Fonction : Auteur
Andreas Viardot
  • Fonction : Auteur
Pier Luigi Zinzani
  • Fonction : Auteur
Anna Sureda
  • Fonction : Auteur

Résumé

The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected salvage algorithms for this condition, and such therapies could have the potential to improve the course of relapsed or refractory LBCL. In this Review, we provide guidance for a rational management approach to the use of commercial CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial questions regarding eligible histologies; age, comorbidity, and tumour biology restrictions; the handling of very aggressive tumour behaviour; and holding and bridging therapies. The guidance was developed in a structured manner and, for each question, consists of a description of the clinical issue, a summary of the evidence, the rationale for a practical management approach, and recommendations. These recommendations could help to decide on the optimal management of patients with relapsed or refractory LBCL who are considered for second-line CAR T-cell treatment.
Fichier non déposé

Dates et versions

hal-04607430 , version 1 (10-06-2024)

Identifiants

Citer

Peter Dreger, Paolo Corradini, John G. Gribben, Bertram Glass, Mats Jerkeman, et al.. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach.. The Lancet Haematology, 2023, The Lancet Haematology, 10, pp.e1006-e1015. ⟨10.1016/S2352-3026(23)00307-1⟩. ⟨hal-04607430⟩

Collections

UNIV-LILLE
3 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More